Neoadjuvant immune checkpoint inhibitor reduced recurrence in operable NSCLC patients with pathological complete response: a retrospective analysis. Mao Y, Chen F, Ye Z, Li Z, et al. BMC Cancer 2024;24:1366.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Mao Y, Chen F, Ye Z, Li Z, et al. Neoadjuvant immune checkpoint inhibitor reduced recurrence in operable NSCLC patients with pathological complete response: a retrospective analysis. BMC Cancer 2024;24:1366.
PMID: 39516761